Peregrine Pharmaceuticals (NASDAQ:PPHM) Analyst Rating Consensus

Peregrine Pharmaceuticals (NASDAQ:PPHM) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.67 by 3 Brokerage Firm. 2 Wall Street Firms have rated the stock as a strong buys. 1 Brokerage Firms have advised hold.

Peregrine Pharmaceuticals (NASDAQ:PPHM): 3 Analyst have given the stock of Peregrine Pharmaceuticals (NASDAQ:PPHM) a near short term price target of $1. The standard deviation reading, which is a measure by which the stock price is expected to swing away from the mean estimate, is at $0.5. The higher price target estimate is at $2 while the lower price estimates are fixed at $1.

Peregrine Pharmaceuticals (NASDAQ:PPHM) witnessed a decline in the market cap on Tuesday as its shares dropped 4.59% or 0.0194 points. After the session commenced at $0.43, the stock reached the higher end at $0.44 while it hit a low of $0.4. With the volume soaring to 1,545,173 shares, the last trade was called at $0.4029. The company has a 52-week high of $1.4. The company has a market cap of $94 million and there are 233,738,430 shares in outstanding. The 52-week low of the share price is $0.2934.

Peregrine Pharmaceuticals, Inc. has dropped 6.3% in the last five trading days, however, the shares have posted positive gains of 3.31% in the last 4 weeks. Peregrine Pharmaceuticals, Inc. has dropped 1.73% during the last 3-month period . Year-to-Date the stock performance stands at -65.56%.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its phosphatidylserine (PS) targeting agent, PGN65, and its brain cancer therapy Cotara. Bavituximab is the Companys therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company is evaluating the bavituximab investigator-sponsored trials (IST) in front-line, HER2-negative metastatic breast cancer, liver cancer, rectal adenocarcinoma and advanced melanoma. It is also evaluating PGN650 imaging in multiple solid tumor types. The Company`s Impavido biomanufacturing subsidiary Avid Bioservices, Inc., provides commercial and clinical manufacturing services for the Company and third-party clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *